CEO and Managing Director, Dr Tim Oldham’s presentation at the TechKnow Invest Roadshow on 19 August 2025 is now available on the Company’s website.

The presentation highlights the two global trends powering AdAlta’s “East to West” strategy:

1. The CAR-T cell therapy revolution: technology enabling the engineering of a patient's own immune cells to fight cancer, creating a living drug where a single dose is potentially a cure

2. The rise of China biotech: creating a now globally respected pool of innovation, particularly in CAR-T cell therapy

The presentation also describes the business system AdAlta is adopting and how successfully deploying it will create value for shareholders. AdAlta will license highly differentiated, clinical stage products at low cost from China ("East"), develop them cost effectively in Australia and then on-license to realise significant value creation in "Western" markets.